Sandoz Takes Aim At Ranbaxy's Generic Nexium Sales Rights

Law360, New York (June 27, 2012, 7:54 PM EDT) -- Sandoz Inc. has asked the U.S. Food and Drug Administration to find that Ranbaxy Laboratories Ltd. forfeited its six-month exclusivity over the sale of a generic version of heartburn drug Nexium, saying it gained approval too late.

India-based Ranbaxy was the first company to submit an abbreviated new drug application for a generic version of AstraZeneca PLC's Nexium, making it eligible for 180 days of exclusive sale rights.

But in a citizen petition dated June 19, Sandoz — Novartis AG's generic pharmaceutical unit — contends that...
To view the full article, register now.